Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Epoch Biosciences, Inc. (NasdaqNM:EBIO)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Location
21720 23rd Drive SE, Suite 150
Bothell, WA 98021
Phone: (425) 482-5555
Fax: (425) 821-7539
Email: llarson@epochpharm.com
Employees (last reported count): 51
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 45%
·Over the last 6 months:
 · 2 insider buys; 145.0K shares (1.3% of insider shares)
·Institutional: 13% (23% of float)
(14 institutions)
·Net Inst. Selling: 236.0K shares (+7.69%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Epoch Biosciences, Inc., formerly Epoch Pharmaceuticals, Inc., is developing and commercializing proprietary technologies to enhance the study of genes. Its scientists are applying their expertise in nucleic acid chemistry to develop products that improve methods of studying the genetic sequence (genomes) of humans, animals and plants. The Company is utilizing its knowledge in DNA chemistry to design, synthesize and modify synthetic DNA strands (probes) that selectively bind to the gene being studied. Using its DNA technology, the Company is developing molecular tools and chemical compounds for improved genetic analysis. Epoch has adapted its chemical compounds and techniques to genetic analysis systems developed by Applied Biosystems and Third Wave Technologies. Applications include the detection of infectious diseases, diagnosis of inheritable diseases through prenatal testing and screening populations to identify genetic markers that correlate with disease risk or drug response.
More from Market Guide: Expanded Business Description

Financial Summary
Epoch Biosciences, Inc. is a biomedical company utilizing nucleoside and nucleotide chemistry to develop molecular tools for genetic analysis, providing products and techniques for high throughput genetic sequence anaylsis. For the six months ended 6/30/01, revenues totaled $3.3 million, up from $239 thousand. Net loss rose 5% to $2.5 million. Results reflect increased chemical intermediate sales, offset by lower profit margins due to product mix and capacity utilization.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Fred Craves, Ph.D., 55
Chairman
$59K--  
William Gerber, M.D., 54
CEO, Director
331K--  
Sanford Zweifach, 45
Pres, Sec., Director
135K$82K
Bert Hogue, 43
CFO, VP-Fin.
--  --  
Merl Hoekstra, Ph.D., 41
VP, Corp. Devel.
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:EBIOAs of 31-Aug-2001
Price and Volume
52-Week Low
on 9-Apr-2001
$2.05 
Recent Price$3.50 
52-Week High
on 1-Sep-2000
$12.438
Beta0.94 
Daily Volume (3-month avg)17.6K
Daily Volume (10-day avg)11.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-68.5%
52-Week Change
relative to S&P500
-57.8%
Share-Related Items
Market Capitalization$89.7M
Shares Outstanding25.6M
Float14.1M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.55 
Earnings (ttm)-$0.19 
Earnings (mrq)-$0.05 
Sales (ttm)$0.17 
Cash (mrq)$0.33 
Valuation Ratios
Price/Book (mrq)6.42 
Price/EarningsN/A 
Price/Sales (ttm)20.38 
Income Statements
Sales (ttm)$4.45M
EBITDA (ttm)-$5.01M
Income available to common (ttm)-$5.02M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-25.95%
Return on Equity (ttm)-31.39%
Financial Strength
Current Ratio (mrq)6.12 
Debt/Equity (mrq)0.00 
Total Cash (mrq)$8.40M
Short Interest
As of 8-Aug-2001
Shares Short4,000 
Percent of Float0.0%
Shares Short
(Prior Month)
5,000 
Short Ratio0.16 
Daily Volume25.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.